Rivoxar is made and published by Jepharm. AppBrain is an independent app data site and isn't affiliated with Jepharm. The app name, icon, screenshots and description belong to Jepharm and are shown as published on the App Store.
AppBrain's verdict
Removed- Rating on App Store
- 5.00
- 1 ratings
- Last updated
- September 12, 2022
Rivoxar is no longer on the App Store. It had too few ratings to say what users thought.
Releases
Updates seen on the App Store- Version
- 2.4.0
- Launched
- June 2021
No changelog data
User feedback
Ratings and reviews on the App StoreComments on Rivoxar for iOS
We don't have enough comments to show example comments. Please check back later.
Technology
Found in the app by AppBrain- Price
- Free
- App size
- 28.2 MB
- Content rating
- Everyone
Technologies used by Rivoxar
About the app and developer
About Rivoxar
Rivoxar was an education app developed by Jepharm. It was removed from the App Store Jan 20, 2026.
User Ratings
Rivoxar was rated 5.00 out of 5 stars, based on one rating ratings.
App Information
Rivoxar was free. The app size was 28.21 MB. The last available version was 2.4.0. The last update was on September 12, 2022.
Technical Requirements
The app had a content rating of Everyone. The app had been available on the App Store since June 2021.
Developer information for Jepharm
Address:
Store listing
By Jepharm, from the App StoreSimilar apps
Description by Jepharm Written by the developer, not by AppBrain. Click to read.
RivoXar Application is a tool to help implement international guidelines into medical practice, it contains highly recommended scores that are related to anticoagulation therapy, it contains Calculators of :
1. CHA2DS2-VASc Score: most commonly utilized method to predict thromboembolic risk in atrial fibrillation.
2. HAS-BLED Score: developed as a practical risk score to estimate the 1-year risk for major bleeding in patients with atrial fibrillation.
3. Other (in Progress).
· The Application is easy to be used, no personal information neither from you or your patients is needed to be able to use The App.
· This guarantees 100% of privacy for you and your patients.
· You can have the Username and Password by contacting Jerusalem Pharmaceutical Company representative.
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
European Heart Journal (2020) 42, 373_498
• CHA2DS2-VASc Calculator - Figure 12 CHA2DS2-VASc
• HAS-BLED Calculator - Table 10 Clinical risk factors in the HAS-BLED score
ESC 2020 Guidelines for AF Management
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management
This app was developed By Newsoft
www.newsoft.ps